Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Avacta advances AVA6000 towards pivotal US trial

Summary by Share Talk
The FDA has agreed that a single pivotal clinical trial could be sufficient to support full regulatory approval of AVA6000 for the treatment of salivary gland cancer, with progression-free survival serving as the sole primary endpoint.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Share TalkShare Talk

Avacta advances AVA6000 towards pivotal US trial

The FDA has agreed that a single pivotal clinical trial could be sufficient to support full regulatory approval of AVA6000 for the treatment of salivary gland cancer, with progression-free survival serving as the sole primary endpoint.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Share Talk broke the news on Thursday, June 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal